Lorazepam, a dichloro-3-hydroxy-1,4-benzodiazepine, has been shown to be a potent anticonvulsant in animal models of epilsepsy and has minimal depressant effects on respiration and circulation in humans. The effects of this compound were studied in status epilepticus. Twenty-five patients were given intravenous lorazepam during status epilepticus of varying cause. Four or 8 mg of the drug controlled status in 22 of the 25 patients. Although single seizures recurred in 5 of the 22 patients, none experienced recurrence of status during a prolonged follow-up period. Transient respiratory arrest occurred in 1 patient, but no other significant complications were observed. Studies of plasma drug levels suggest that most patients attain good seizure control at concentrations between 30 and 100 ng per milliliter. Clinical observations indicate that repetitive injections are not required for continuing control of seizures in patients whose seizures are initially controlled. Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam.
Chondrodystrophia calcificans congenita is a poorly understood and infrequently recognized condition. Early diagnosis is important for genetic counseling and proper management. Two living patients and three autopsied cases were studied. All had pathognomonic facies with deficient nasal bones producing a saddle nose deformity, micromelia, rhizomelia, and characteristic roentgenograms in the first year of life with punctate deposits of calcium in the preosseous and osseous cartilage of the body. Neurological manifestations were common. One with cerebral atrophy had spastic diplegia, optic atrophy, and severe psychomotor retardation, and another had a Dandy\x=req-\ Walker malformation. Cataracts, congenital heart disease, joint contractures, dislocated hips, skin rash with alopecia, and failure to thrive resulting in early death were also observed. Multisystem involvement suggests an underlying inborn error of metabolism.Si nce Conradi1 described the first case of this condition in 1914 un¬ der the name, chondrodystrophia fetalis hypoplastica, the diagnosis of chondrodystrophia calcificans con¬ genita has been established primarily upon radiological evidence of tiny punctate calcifications in the region of epiphyseal centers. A review of the literature 2~4 indicates that the of age. Other than distortion of some of the affected epiphyses, roentgeno¬ grams are of no value as a diagnostic tool in older children. Yet, until now, it has been virtually impossible to diagnose chondrodystrophia calcificans congenita unless the char¬ acteristic stippling has been pres¬ ent.5 A varied chnical picture is re¬ sponsible for this "hit or miss" de¬ tection of the disorder. Although several authors68 have attempted to define the chnical manifestations of this entity, no specific chnical pic¬ ture is available. A study of more than 100 cases reported in the litera¬ ture 5"15 revealed a bewildering va¬ riety of manifestations indicative of multisystem involvement which in¬ cludes not only the skeletal but the cardiovascular, cutaneous, renal, and central nervous systems (CNS) as well.In an attempt to clarify the clinical picture of chondrodystrophia calcificans congenita, we have devised a set of presenting signs and symptoms highly suggestive of this entity. These manifestations have been di¬ vided into a constant group com¬ prised of those most commonly en¬ countered and a variable group. We consider the combination of the con¬ stant group with three or more vari¬ able group findings to be suggestive evidence of this condition. Our out¬ line is based on a review of the literature and a study of two hving patients and three autopsied cases observed at the Columbia-Presby¬ terian Medical Center (CPMC). Report of CasesCase 1.-This patient (Fig 1) was re¬ ferred to CPMC at 18 months of age for evaluation of psychomotor retardation. This was evidenced by his inability to sit alone, bear weight on his legs, see, speak, or hear. The gestation period had been full term and the delivery normal, with a birth weight of 3,740 gm (8 lb 4 oz), ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.